Acute Bronchitis Clinical Trial
— HL301Verified date | September 2014 |
Source | Hanlim Pharm. Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Ministry of Food and Drug Safety |
Study type | Interventional |
The purpose of this study is to determine the optimal dose of HL301 in patients with acute
bronchitis or acute exacerbations of chronic bronchitis.
- BSS(Bronchitis Severity Score), BCSS(Breathlessness, Cough, and Sputum Scale), evaluation
of symptoms of cough and sputum
Status | Completed |
Enrollment | 156 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Both gender, 19 years = age = 80 years 2. Acute bronchitis or acute exacerbations of chronic bronchitis patients with BSS(Bronchitis Severity Score)* = 5point at Visit1 and Visit2 3. Written consent voluntarily to participate in this clinical trial Exclusion Criteria: 1. Patients who were increased the bleeding tendency 2. Patients with any of Alanine aminotransferase, Aspartate aminotransferase or serum Blood Urea Nitrogen, Creatinine> 2 times of the normal upper range 3. Patients who investigators determines to severe respiratory disease that would interfere with study assessment 4. Patients with COPD(Chronic Obstructive Pulmonary Disease) history of stage 3 or more 5. Patients who were treated with oral systemic adrenocortical hormone or immunosuppressive drug within 4 weeks prior to study participation 6. Patients who were treated with oral ß2-agonist, anticholinergic, Methylxanthine, antibiotics, antihistamines, sympathomimetic agent or oriental medicine/health functional food for antitussive and mucolytic Effect within 1 weeks prior to study participation 7. Patients who were treated with oral Antitussive, Mucolytic Agents,systemic antimicrobial agent within 3 days prior to study medication dosing 8. Patients with drug or alcohol abuse 9. Patients with clinically significant active liver, renal, cardiovascular, respiratory, endocrine, central nervous system disease or history of malignant tumor or mental illness(except no relapse for 5 years after surgery) 10. The aged person with severe medical history which is mental disorder(dementia), cancer, chronic renal failure, chronic liver failure 11. Pregnant or breast-feeding 12. Patients currently participating in or has participated in other clinical study within 30 days prior to study participation 13. Patients who investigators determines not appropriate to take part in this clinical study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Kyung Hee University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Hanlim Pharm. Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bronchitis Severity Score | Bronchitis Severity Score | baseline(day 0) and day 7 | No |
Secondary | Breathlessness, Cough, and Sputum Scale | Breathlessness, Cough, and Sputum Scale | baseline(day 0) and day 7 | No |
Secondary | evaluation of symptoms of cough and sputum | baseline(day 0) and day 7 | No | |
Secondary | Total usage of acetaminophen | baseline(day 0) and day 7 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03711292 -
Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings
|
N/A | |
Not yet recruiting |
NCT03517215 -
The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program
|
N/A | |
Completed |
NCT01420445 -
Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis
|
Phase 2 | |
Completed |
NCT00360464 -
A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases
|
Phase 3 | |
Completed |
NCT05344638 -
A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis
|
Phase 3 | |
Completed |
NCT06457269 -
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
|
N/A | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Recruiting |
NCT03827590 -
Clinical Trials to Assess the Efficacy and Safety of HLIM
|
Phase 3 | |
Completed |
NCT02792946 -
Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
|
Phase 3 | |
Completed |
NCT01875757 -
Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life
|
Phase 3 | |
Recruiting |
NCT04252963 -
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
|
Phase 4 | |
Recruiting |
NCT06411925 -
The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients
|
Phase 4 | |
Completed |
NCT01416480 -
Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher
|
Phase 3 | |
Enrolling by invitation |
NCT05916768 -
Management of Acute Bronchitis With Pelargonium Sidoides Extract
|
N/A | |
Completed |
NCT03309800 -
A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients
|
Phase 2 | |
Not yet recruiting |
NCT03310385 -
Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis
|
Phase 2 | |
Completed |
NCT03654196 -
A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
|
Phase 3 | |
Completed |
NCT03011515 -
Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
|
||
Completed |
NCT02045394 -
Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study
|
N/A | |
Completed |
NCT01800747 -
Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics)
|
Phase 4 |